Please assess the completion status of the following clinical trial:

Trial Title: IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~Adult Lead-in Cohort~1. Individuals who are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the investigator.~2. Completed primary immunization against poliomyelitis according to local recommendations.~Toddler Lead-in Cohort~1. Toddlers in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the investigator.~2. Completed primary immunization against poliomyelitis, preferably with IPV, according to local recommendations.~Infant Dose Ranging Cohort 1. Infants are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the investigator.~3. Infants must have been born full term (37-42 weeks of gestation).~Exclusion Criteria:~Adult Lead-in Cohort~1. Has body mass index (BMI) greater than or equal to 35 kg/m\^2 (= weight in kg \[height in meters \* height in meters\].~Toddler Lead-in Cohort~1. Last polio vaccination (either inactivated or oral) received within 5 months prior to first trial visit.~2. Household member/sibling who had received or is/are scheduled to receive Oral Poliomyelitis Vaccine (OPV) in the previous 3 months until 5 weeks post participant's inclusion in the study.~3. Prior vaccination with booster dose of diphtheria, tetanus, pertussis (acellular or whole cell), polio (either inactivated or oral), or Haemophilus influenzae type b (Hib) vaccines.~Infant Dose Ranging Cohort~1. Infants with low birth weight according to local standards.~2. Prior vaccination with polio vaccines (either inactivated or oral).~3. Household member/sibling that had received or is/are scheduled to receive OPV in the previous 3 months until 5 weeks after the third dose of the primary immunization series.~4. Prior vaccination with any diphtheria, tetanus, pertussis (acellular or whole cell), Haemophilus influenzae type b (Hib) vaccine or polio vaccine (OPV or IPV). Note, bacillus Calmette Guérin (BCG) at birth and prior vaccination with Hepatitis B vaccine given at least 4 weeks prior to first trial visit are not exclusion criteria.~All Cohorts~1. Any significant chronic infection.~2. Any clinically significant active infection (as assessed by the investigator) or temperature ≥38.0°C (\>100.4°F), within 3 days of intended trial vaccination.~3. Known or suspected impairment/alteration of immune function, including:~   1. Chronic use of oral steroids (equivalent to 20 mg/day prednisone for ≥12 weeks/≥2 mg/kg body weight/day for ≥2 weeks) within 60 days prior to Day 1 (use of inhaled, intranasal, or topical corticosteroids is allowed).~  2. Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥2 mg/kg body weight/day for ≥2 weeks) within 60 days prior to Day 1.~  3. Administration of immunoglobulins and/or any blood or blood products within the 3 months preceding the administration of the trial vaccine or planned administration during the trial~  4. Receipt of immunostimulants within 60 days prior to Day 1.~  5. Genetic immunodeficiency.~4. Has a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Adult Lead-in Cohort: sIPV High Dose (Type: EXPERIMENTAL): Sabin-based inactivated poliomyelitis vaccine (sIPV) containing 3, 100, and 100 D-Ag units (DU) of poliovirus types 1, 2, and 3, intramuscular injection on Day 1.
- Adult Lead-in Cohort: Placebo (Type: PLACEBO_COMPARATOR): Placebo, intramuscular injection on Day 1.
- Toddler Lead-in Cohort: sIPV High Dose (Type: EXPERIMENTAL): sIPV containing 3, 100, and 100 DU of poliovirus types 1, 2, and 3, intramuscular injection on Day 1.
- Toddler Lead-in Cohort: Reference IPV (Type: ACTIVE_COMPARATOR): Reference IPV, intramuscular injection on Day 1.
- Infant Dose Ranging Cohort: sIPV Low Dose (Type: EXPERIMENTAL): sIPV containing 0.75, 25, 25 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29, 57 and 365.
- Infant Dose Ranging Cohort: sIPV Medium Dose (Type: EXPERIMENTAL): sIPV containing 1.5, 50, 50 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29 57 and 365.
- Infant Dose Ranging Cohort: sIPV High Dose (Type: EXPERIMENTAL): sIPV containing 3, 100, 100 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29 57 and 365.
- Infant Dose Ranging Cohort: Reference IPV (Type: ACTIVE_COMPARATOR): Reference IPV, intramuscular injection on Days 1, 29 57 and 365.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility